FindTrial
Sign In

Evaluation of tolerability and analgesic activity of paracetamol 1000 mg+caffeine 130 mg in the treatment of tension-type headache. Randomized, double blind, double-dummy, cross-over study vs. naproxene 550 mg and placebo.

Evaluation of tolerability and analgesic activity of paracetamol 1000 mg+caffeine 130 mg in the treatment of tension-type headache. Randomized, double blind, double-dummy, cross-over study vs. naproxene 550 mg and placebo.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-000850-22-IT
Enrollment
Unknown
Registered
2005-02-02
Start date
2004-09-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of tolerability and analgesic activity in the treatment of tension-type headache Level: PT Classification code 10043269

Interventions

Trade Name: Anilidi Product Name: Anilides Pharmaceutical Form: Effervescent granules INN or Proposed INN: paracetamol+caffeine Current Sponsor code: 044(2A)SC04030 Concentration unit: mg milligram(

Sponsors

ANGELINI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026